Press releases

US patent granted for Tumorad®

Spago Nanomedical AB (publ) announce today that the United States Patent and Trademark Office (USPTO) has granted the company´s patent application comprising product protection for Tumorad® in the USA.
Read more

Spago Nanomedical select CTC for the first clinical trial with SpagoPix

Spago Nanomedical AB has signed an agreement with the Swedish clinical CRO CTC Clinical Trial Consultants AB for the conduct of the first clinical study with SpagoPix.
Read more

SpagoPix shows good safety in regulatory preclinical studies

Spago Nanomedical AB (publ) has completed the in-life part of the regulatory preclinical program with SpagoPix. The product candidate SN132D displays a good safety margin to clinically relevant doses.
Read more

Spago Nanomedical receives grant from Vinnova for the development of SpagoPix

Spago Nanomedical has been granted 500 000 SEK by Sweden's government agency for innovation, Vinnova, to support the clinical development and commercialization of SpagoPix.
Read more

Spago Nanomedical to be granted US patent for Tumorad®

Spago Nanomedical have received a Notice of Allowance indicating that the United States Patent and Trademark Office (USPTO) intend to grant the company´s patent application comprising product protection for Tumorad® in the USA.
Read more

Spago Nanomedical directs share issue of 8.7 MSEK to HealthInvest Small & MicroCap Fund

Spago Nanomedical AB implement a directed share issue of 8.7 MSEK to HealthInvest Small & MicroCap Fund. A total of 860 000 shares are issued for a subscription price of 10.15 SEK per share. The subscription price correspond to the volume weighted average share price for the two weeks preceding the…
Read more

SpagoNanomedical select ChemConnection for SpagoPix production to supply clinical trials

Spago Nanomedical AB has signed an agreement with ChemConnection BV, a well-established contract manufacturer with extensive experience in the GMP-production of nanomedical products, for the manufacture of the SpagoPix product candidate SN132D for clinical trials.
Read more

The Rights Issue in Spago Nanomedical AB was oversubscribed

PRESS RELEASE Lund 24 October 2017 The rights issue in Spago Nanomedical AB (publ) was subscribed to approximately 124%. Spago thereby receives approximately SEK 48.7 million in capital before deduction of issue costs. "The confidence shown in the company and our projects is very encouraging. We can now fully focus…
Read more

The board of Spago Nanomedical AB (publ) resolves on a rights issue prior to clinical studies

PRESS RELEASE Lund 22 August 2017 The Board of Directors (the “Board”) of Spago Nanomedical AB (publ) ("Spago" or the “Company") has given notice for an extraordinary general meeting to be held for the purpose of approving the Board's resolution regarding an issuance of units consisting of shares and warrants…
Read more

Spago Nanomedical and Charles River Laboratories announce agreement forpreclinical studies of SpagoPix

Spago Nanomedical has selected Charles River Laboratories, a leading global CRO, to conduct regulatory preclinical toxicology and safety studies of SpagoPix before clinical trials.
Read more